Immune thrombocytopenic purpura--from agony to agonist.

@article{Schwartz2007ImmuneTP,
  title={Immune thrombocytopenic purpura--from agony to agonist.},
  author={Robert S. Schwartz},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 22},
  pages={
          2299-301
        }
}
  • R. Schwartz
  • Published 29 November 2007
  • Medicine
  • The New England journal of medicine
In the summer of 1950, two hematology fellows working at the Barnes Hospital in St. Louis — William J. Harrington and James W. Hollingsworth — hatched a plan to test their idea that the cause of th... 

Figures from this paper

ITP in Children: Pathophysiology and Current Treatment Approaches
TLDR
Current concepts of the pathophysiology and treatment approaches to pediatric primary immune thrombocytopenia are discussed.
Immunopathogenesis, Immunomodulation and Management of Immune Thrombocytopenic Purpura in Children
TLDR
The bleeding disorder immune thrombocytopenic purpura is a model for immunological research and new biological treatment modalities of chronic inflammatory and autoimmune disorders and children have mostly a transient or persistent form and rarely have a chronic form.
Idiopathic thrombocytopenic purpura
TLDR
A case report on ITP with clinical presentation, diagnosis and management is presented and treatment should be restricted to those patients with moderate or severe thrombocytopenia who are bleeding or at risk of bleeding.
Eltrombopag in Good's Syndrome
TLDR
A male patient suffering from Good's syndrome with immune-mediated T-cell driven pancytopenia and absence of megakaryopoiesis was successfully treated with eltrombopag resulting in a multilineage clinical response.
Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases
TLDR
Immune thrombocytopenic purpura is an autoimmune condition characterized by low platelet count with mucocutaneous and other bleedings and may represent one of the most striking discoveries in human history that changed dramatically life expectancy following vaccination.
Thrombocytopenia in Pregnancy.
TLDR
The aim of this study is to review the specific causes of thrombocytopenia in pregnancy, their obstetrical implications and management.
Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthy.
TLDR
For the first time, CIK cell therapy was reported to be followed by ITP and a better understanding of this rare condition will require further investigation of these cases.
Maternal thrombocytopenia in pregnancy
TLDR
This review provides a detailed discussion of the diagnosis and management of the various causes of thrombocytopenia in pregnancy.
Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines
TLDR
Early recognition of the underlying microbial trigger and the removal of modifiable aetiopathogenetic factors should be integrated as a complementary treatment strategy in all patients who do not readily improve with standard ITP care.
...
...

References

SHOWING 1-10 OF 13 REFERENCES
Immune thrombocytopenic purpura.
TLDR
The authors of this up-to-date review discuss the current understanding of pathophysiology and, in particular, the way in which autoantibodies against platelets are generated.
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.
TLDR
Two patients who were demonstrated to have the platelet-reducing factor prior to splenectomy still had the factor present after platelet counts had returned to normal following removal of the spleen, and the thrombocytopenic factor was found in the globulin fraction.
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
TLDR
Eltrombopag increased platelet counts in a dose-dependent manner in patients with relapsed or refractory ITP, and Bleeding also decreased during treatment in these two groups.
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
TLDR
This report begins with a brief summary of the panel’s recommendations, followed by a more detailed analysis of its methodology, the findings of the comprehensive literature review, and a full presentation of the recommendations.
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation.
TLDR
The data suggest that the development of platelet-reactive antibodies associated with ITP is driven by an encounter with diverse platelet antigens through the clonal expansion of B cells using genetically restricted and highly specific combinations of heavy- and light-chain gene products.
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.
TLDR
Megakaryocyte mass, reflected in the rate of platelet production, appears to be the major determinant of TPO levels in thrombocytopenic patients rather than circulating platelet levels per se, and measurement of serum TPO may be useful in differentiating thromBocytopenias due to peripheral destruction from those due toThrombopoietic failure.
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.
TLDR
It is shown that plasma autoantibody from some adult patients with ITP inhibits in vitro megakaryocyte production, suggesting that a similar effect may occur in vivo.
Autoimmune thrombocytopenia: flow cytometric determination of platelet‐associated autoantibodies against platelet‐specific receptors
TLDR
The present FCM assay is clinically useful for routine diagnosis and follow-up of ITP and compared with the radioactive immunobead assay previously reported on the same cohort of patients showed significant correlation.
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
TLDR
Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.
TLDR
Most ITP megakaryocytes show ultrastructural features of (para-) apoptosis, probably due to action of factors present in ITP plasma.
...
...